Viewing data from:

AMABELZ

ANDA

ESTRADIOL; NORETHINDRONE ACETATE | A203339 | LUPIN LTD

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Amabelz (2023)

Total Spending

$69K

Total Claims

449

Beneficiaries

208

Avg Cost/Unit

$2.01

Spending Trend

$825K(2019)→$573K(2020)→$523K(2021)→$176K(2022)→$69K(2023)

YoY Change:-11.3%

5yr CAGR:-4.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (2)

Sort:

#001 — 0.5MG;0.1MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jun 20, 2016

No patent or exclusivity listings for this strength.

#002 — 1MG;0.5MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 20, 2016